Yahoo · Oct 12, 2026
ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting
Trial met both co-primary endpoints of mean change from baseline in BCVA letter score and mean change from baseline in CST with statistical significance1 at 6 months, and these changes were maintained at 24 months (a key secondary endpoint)The most common adverse events reported were consistent with prior trials of fluocinolone acetonide intravitreal implant 0.18 mgStudy evaluated patients with chronic NIU-PS in the U.S.; most patients in the study were treated by retina specialists PRINCETON, N
